A trend towards more frequent abnormally elevated levels of ALP and liver transaminases was observed in omalizumab-treated subjects vs. placebo recipients; ALT: omalizumab 11.8% (8/68) vs. placebo 7.2% (5/69); AST: omalizumab 10.3% (7/68) vs. placebo 7.2% (5/69) and ALP: omalizumab 20.6% (14/68) vs. placebo, 8.7% (6/69). This evidence concerns the gene GPT and digestive system neoplasm.